Pilot and Preliminary Studies of Thrombolytic Therapy for Stroke

  • Steven R. Levine
  • E. Clarke Haley
  • Patrick Lyden
Part of the Current Clinical Neurology book series (CCNEU)


The demonstration that tissue plasminogen activator (t-PA) is clinically effective for acute ischemic stroke was based on many important studies over the past two decades that then led to groundbreaking preliminary clinical trials. This chapter highlights and discusses these studies and their historical significance. Thrombolytic therapy is an inherently attractive treatment for ischemic stroke based on the known pathological and angiographic substrates of ischemic cerebrovascular disease (see  Chapters 1 3). The majority of acute ischemic strokes are the direct consequences of atherothrombosis or thromboembolism of a cerebral or precerebral artery (see  Chapter 2). The critical event is usually the formation of an acute thrombus, so the rationale for thrombolytic treatment is to achieve arterial recanalization with a relatively safe agent soon enough to improve patient outcome.


Acute Ischemic Stroke Thrombolytic Therapy Tissue Plasminogen Activator Stroke Onset Hemorrhagic Transformation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fieschi C, Argentino C, Lenzi GL, Sacchetti ML, Toni D, Bozzao L. Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours. J Neurol Sci 1989;91: 311–321.PubMedCrossRefGoogle Scholar
  2. 2.
    Saito I, Segawa H, Shiokawa Y, Taniguchi M, Tsutsumi K. Middle cerebral artery occlusion: correlation of computed tomography and angiography with clinical outcome. Stroke 1987;18:863–868.PubMedGoogle Scholar
  3. 3.
    Meyer JS, Herndon R, Gotoh F, Tazaki Y, Nelson JN, Johnson J. Therapeutic Thrombolysis. In: Millikan C, Siekert RG, Whisnant JP, eds., Cerebral Vascular Disease, Third Princeton Conference. New York: Guren and Stratton; 1961:160–177.Google Scholar
  4. 4.
    Meyer JS, Gilroy J, Barnhart ME. Therapeutic Thrombolysis in Cerebral Thromboembolism. In: Siekert RG, Whisnant J, eds., Cerebral Vascular Diseases. Philadelphia: Grune & Stratton;1963:160–175.Google Scholar
  5. 5.
    Meyer JS, Gilroy J, Barnhart ME, Johnson JF. Therapeutic thrombolysis in cerebral thromboembolism: Randomized evaluation of intravenous streptokinase. In: Millikan CH, Siekert RG, Whisnant JP, eds., Cerebral Vascular Diseases, Fourth Princeton Conference. New York: Grune and Stratton; 1965:200–213.Google Scholar
  6. 6.
    Clarke RL, Clifton EE. The treatment of cerebrovascular thrombosis and embolism with fibrinolytic agents. Am J Cardiol 1960;30:546–551.CrossRefGoogle Scholar
  7. 7.
    Clifton EE. The use of plasmin in humans. Ann NY Acad Sci 1957;68:209–229.CrossRefGoogle Scholar
  8. 8.
    Clifton EE. Early experience with fibrinolysin. Angiology 1959;10:244–252.Google Scholar
  9. 9.
    Meyer JS, Gilroy J, Barnhart KT, Johnson JF. Therapeutic Thrombolysis in Cerebral Thromboembolism. Double-Blind Evaluation of Intravenous Plasmin Therapy in Carotid and Middle Cerebral Arterial Occlusion. Neurology 1963; 13:927–937.PubMedGoogle Scholar
  10. 10.
    Meyer JS, Gilroy J, Barnhart ME, and Johnson JF. Anticoagulants plus streptokinase therapy in progressive stroke. Journal of the American Medical Association 189, 373. 1964.Google Scholar
  11. 11.
    Sussman B, Fitch T. Thrombolysis with fibrinolysin in cerebral arterial occlusion. JAMA 1958; 167:1705–1709.Google Scholar
  12. 12.
    Clifton EE. The use of plasmin in the treatment of intravascular thormbosis. J Am Geriatr Soc 1958; 6:118–127.Google Scholar
  13. 13.
    Herndon R, Meyer JS, Johnson JF, Landers J. Treatment of cerebrovascular thrombosis with fibrinolysin. Preliminary report. Am J Cardiol 1960;6:540–545.PubMedCrossRefGoogle Scholar
  14. 14.
    Herndon R, Meyer JS, Johnson JF. Fibrinolysin therapy in thrombotic diseases of the nervous system. J Mich State Med Soc. 1960;59:1684–1692.PubMedGoogle Scholar
  15. 15.
    Fletcher AP, Alkjaersig N, Lewis M, et al. A pilot study of urokinase therapy in cerebral infarction. Stroke 1976;7:135–142.PubMedGoogle Scholar
  16. 16.
    Larcan A, Laprevote-Heully MC, Lambert H, Alexandre P, Picard L, Chrisment N. [Indications for the use of thrombolytics in cases of cerebrovascular thrombosis also treated with hyperbaric oxygenation (2 ATA)]. Therapie 1977;32:259–270.PubMedGoogle Scholar
  17. 17.
    Theron AJ, Courtheoux P, Casasco A, et al. Local intraarterial fibrinolysis in the carotid territory. Am J Neuroradiol 1989;10:753–756.PubMedGoogle Scholar
  18. 18.
    Zeumer H, Freitag H-J, Zanella F, Thise A, Arning C. Local intra-arterial thrombolytic therapy in patients with stroke: urokinase versus recombinant tissue plasminogen activator (rt-PA). Nrad 1993;35: 159–162.Google Scholar
  19. 19.
    del Zoppo G, Zeumer H, Harker LA. Thrombolytic therapy in stroke: Possibilities and hazards. Stroke 1987;17:595–607.Google Scholar
  20. 20.
    del Zoppo G, Ferber A, Otis S, et al. Local intra-arterial fibrinolytic therapy in acute cartoid territory stroke. Stroke 1988;19:307–313.PubMedGoogle Scholar
  21. 21.
    Abe T, Kazawa M, Naito I, et al. Clinical effect of urokinase (60,000 units/day) on cerebral infarction—comparative study by means of multiple center double blind test. Blood Vessel 1981;12:342–358.Google Scholar
  22. 22.
    Fujishima M, Omae T, Tanaka K, Iino K, Matsuo O, Mihara H. Controlled trial of combined urokinase and dextran sulfate therapy in patients with acute cerebral infarction. Angiology 1986;37:487–498.PubMedGoogle Scholar
  23. 23.
    Hacke W, Zeumer H, Ferbert A, Bruckmann H, del Zoppo G. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke 1988;19:1216–1222.PubMedGoogle Scholar
  24. 24.
    Bruckmann H, Ferbert A, del Zoppo G, Hacke W, Zeumer H. The acute vertebro-basilar thrombosis. Angiological-clinical comparison and therapeutic implications. Acta Radiol 1987;369(suppl):38–42.Google Scholar
  25. 25.
    del Zoppo GJ, Ferbert A, Otis S, et al. Local intra-arterial fibrinolytic therapy in acute carotid territory stroke. A pilot study. Stroke 1988;19:307–313.PubMedGoogle Scholar
  26. 26.
    Mori E, Tabuchi M, Yoshida T, Yamadori A. Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery. Stroke 1988;19:802–812.PubMedGoogle Scholar
  27. 27.
    Terashi A, Kobayashi Y, Katayama Y, Inamura K, Kazama M, Abe T. Clinical effects and basic studies of thrombolytic therapy on cerebral thrombosis. Semin Thromb Hemost 1990;16:236–241.PubMedCrossRefGoogle Scholar
  28. 28.
    Hennerici, M., Hacke, W, von Kummer, R., Hornig, C. R., and Zangemeister, W. Intravenous tissue plasminogen activator for the treatment of acute thromboembolic ischemia. Cerebrovasc Dis 1991;Suppl 1: 124–128.CrossRefGoogle Scholar
  29. 29.
    von Kummer R, Hacke W. Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke. Stroke 1992;23:646–652.Google Scholar
  30. 30.
    Overgaard K, Sperling B, Boysen G, et al. Thrombolytic therapy in acute ischemic stroke: A Danish pilot study. Stroke 1993;24:1439–1446.PubMedGoogle Scholar
  31. 31.
    Brott TG, Haley EC, Jr., Levy DE, et al. Urgent therapy for stroke: Part 1. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992;23:632–640.PubMedGoogle Scholar
  32. 32.
    Haley EC, Jr., Levy DE, Brott TG, et al. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91–180 minutes from onset. Stroke 1992;23:641–645.PubMedGoogle Scholar
  33. 33.
    del Zoppo G, Poeck K, Pessin MS, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992;32:78–86.PubMedCrossRefGoogle Scholar
  34. 34.
    Yamaguchi T, Hayakawa T, Kikuchi H, Abe T. Intravenous rt-PA in embolic and thrombotic cerebral infarction: A cooperative study. In: Hacke W, del Zoppo G.J., Hirshberg M, eds., Thrombolytic Therapy in Acute Ischemic Stroke. Berlin: Springer-Verlag; 1991:168–174.Google Scholar
  35. 35.
    Mori E, Yoneda Y, Tabuchi M, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992;42:976–982.PubMedGoogle Scholar
  36. 36.
    Haley EC, Brott TG, Sheppard GL, et al. Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. Stroke 1993;24:1000–1004.PubMedGoogle Scholar
  37. 37.
    The Ancrod Stroke Study Investigators. Ancrod for the treatment of acute ischemic brain infarction. Stroke 1994;25:1755–1759.Google Scholar
  38. 38.
    Hossmann V, Heiss W-D, Bewermeyer H, Wiedemann G. Controlled trial of ancrod in ischemic stroke. Arch Neurol 1983;40:803–808.PubMedGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2005

Authors and Affiliations

  • Steven R. Levine
    • 1
  • E. Clarke Haley
    • 2
  • Patrick Lyden
    • 3
    • 4
  1. 1.Stroke Program, Department of NeurologyThe Mount Sinai School of Medicine and Medical CenterNew York
  2. 2.Department of NeurologyUniversity of Virginia Health SystemCharlottesville
  3. 3.UCSD Stroke CenterUniversity of CaliforniaSan Diego
  4. 4.Veteran’s Affairs Medical CenterSan Diego

Personalised recommendations